|
gptkbp:instanceOf
|
gptkb:drug
biguanide
|
|
gptkbp:approvedInUS
|
1995
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:chemicalFormula
|
biguanide derivative
|
|
gptkbp:contraindication
|
gptkb:liver_disease
renal impairment
|
|
gptkbp:discoveredBy
|
gptkb:James_Bell
gptkb:Emile_Werner
|
|
gptkbp:discoveredIn
|
1922
|
|
gptkbp:eliminationHalfLife
|
4–8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C4H11N5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Metforminum
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:meltingPoint
|
223–226 °C
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:synonym
|
gptkb:metformin
|
|
gptkbp:usedFor
|
gptkb:polycystic_ovary_syndrome
gptkb:type_2_diabetes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:DB00740
gptkb:DB00783
|
|
gptkbp:bfsLayer
|
6
|